Company
Numinus Wellness Inc.
TSE:NUMI
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
74 stories · page 2 of 4
Numinus Wellness unveils revamped podcast series with additional hosts and expanded topics
The podcast episodes will span diverse themes, featuring engaging conversations around psychedelics, research and the therapy that makes them powerful agents for lasting change in mental health, Numinus Wellness said
Numinus Wellness launches Ketamine for Chronic and Serious Medical Illness Program
The program will offer ketamine-assisted therapy alongside additional community support, focusing on improving patients’ physical, emotional, mental and spiritual suffering caused by illness
Numinus Wellness develops psilocybin-infused tea bag for use in psychedelic research
The company said that it recognized that solid therapeutic products, such as whole mushrooms or pills, might be unappealing or difficult to use by certain populations, such as people receiving palliative care for serious illnesses
Numinus Wellness announces opening of new clinic with expanded capacity in Montreal
"Expanding our services here is another important step towards improving access to best-in-class and innovative mental healthcare in Quebec, while continuing to expand our clientele and market presence," said Numinus founder and CEO Payton
Numinus Wellness says its Toronto clinic now offering ketamine-assisted therapy
“By offering these additional services, we can help alleviate their distress and improve their quality of life,” Numinus Wellness CEO Payton Nyquvest said
Numinus Wellness updates on integration of Novamind acquisition
"We continue to be pleased with the performance of our recently acquired US clinics - and their continued success in building strong client relationships," Payton Nyquvest, founder and CEO said
Numinus Wellness sees fiscal 3Q revenue rise by 31.8% thanks to new acquisitions Mindspace and the Neurology Centre of Toronto
For the period ended May 31, 2022, the Vancouver-based leader in psychedelics-focused mental healthcare, reported revenue of $0.74 million
Numinus Wellness launches new visual brand identity
"Our new updated identity will be instrumental for Numinus as we expand our market presence, drive increased brand awareness, and, ultimately, advance as a leader in psychedelic-assisted therapy and mental health care across North America,"
Numinus Wellness says piloting program to offer ketamine-assisted psychotherapy as a health benefit for eligible employees
Numinus' Utah-based clinics, Cedar Psychiatry, and HempLucid, a Utah-based provider of premium wellness products, have teamed up to ensure that employees with a mental health diagnosis can access care
Numinus applies for international patent for psychedelics production process
"This application is part of Numinus' long-term IP strategic focus on scalable and sustainable production that advances research, development and delivery of innovative psychedelic-derived formulations in North America and beyond," said Pay
Numinus Wellness completes acquisition of Novamind; announces executive team expansion
The acquisition has positioned the company as a leading integrated mental wellness company providing ketamine- and psychedelic-assisted therapies, with 13 wellness clinics, four clinical research facilities and a dedicated psychedelics rese
Numinus Wellness says shareholders have approved resolution in connection with the proposed acquisition of Novamind
"This acquisition will position our business as one of the leading integrated mental wellness companies in North America offering Ketamine- and psychedelic-assisted therapies, with 13 wellness clinics, four clinical research sites and a ded
Numinus Wellness granted Health Canada approval for psychedelic-assisted therapy using psilocybin for patient with treatment-resistant depression
The psychedelic-assisted therapy treatment, which the company said has shown a great deal of promise in treating depression in recent clinical trials and studies, will take place at one of Numinus’ Montreal clinics
Numinus Wellness announces concert series exploring role of music in psychedelic-assisted therapy
The events will be hosted in various cities across the United States and Canada, with the first event to take place in Los Angeles on May 21, 2022, at Lighthouse Immersive
Numinus Wellness sees fiscal 2Q revenue soar by 240% thanks to its robust wellness clinic acquisitions
For the three-month period ended February 28, 2022, the Vancouver-based mental healthcare company advancing innovative treatments and psychedelic-assisted therapies reported revenue of $0.8 million
Numinus Wellness strikes deal to acquire US psychedelic healthcare company Novamind for C$26.2M
Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization in the US
Numinus Wellness completes first MDMA administration in PTSD trial sponsored by MAPS
"We are proud of our clinical and research teams who have been and continue to be instrumental in driving MDMA-assisted therapy for PTSD research forward in Canada," said Payton Nyquvest, CEO and founder of the company
Numinus Wellness says its research lab receives new biosecurity license for expansion
The addition will contribute novel data on natural psychedelics, presenting additional intellectual property (IP) opportunities and another revenue driver through contract research services